HOME >> BIOLOGY >> NEWS
New genetic technique delivers knockout blow to 'Asthma Virus'

The respiratory syncytial virus (RSV) is the major cause of asthma and respiratory illness in children, claiming around a million lives each year. New research published in BMC Microbiology reveals how synthetic inhibitory double stranded RNA (siRNA) can be used to knock out the function of specific RSV genes. This technique will be exceptionally useful in furthering understanding of RSV and related viruses. In addition, it could lead to the development of new treatments to combat such viruses.

Most organisms use double stranded DNA to store their genetic information. However, some viruses use single or double stranded RNA instead. Among those that use single stranded RNA are RSV and the viruses responsible for influenza, measles, mumps, rabies, lassa fever and ebola. These organisms present unique challenges to researchers, as they cannot be studied using conventional genetic techniques, which are designed for DNA.

Vira Bitko and Sailen Barik from the University of Alabama used a technique called "post-translational gene silencing" whereby specific siRNA molecules are synthesised and used to target specific regions of the virus RNA. The researchers found that when siRNA was introduced into virus-infected cells, the production of specific viral proteins were blocked and that replication of the virus could be efficiently suppressed. Furthermore, there was no detectable effect on the gene expression of the host cell confirming that the technique specific to the RNA virus. They were also able to show that siRNA acts by a mechanism that does not involve the interferon response that is triggered by viral infections.


'"/>

Contact: Gordon Fletcher
gordon@biomedcentral.com
44-20-7323-0323
BioMed Central
15-Jan-2002


Page: 1

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Rare childhood genetic syndrome identified
3. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
4. Scientists decipher genetic code of biothreat pathogen
5. Chemical genetics identifies SARS inhibitors
6. 22nd amino acid synthesized and added to genetic code of e. coli bacteria
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. Adaptive changes in the genome may provide insight into the genetics of complex disease
9. New genetic hypothesis for the cause of autism
10. Fossils reveal direct link between global warming and genetic diversity in wildlife
11. A genetic disorder yields insight into genes and cognition

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New genetic technique delivers knockout blow Asthma Virus

(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Cached News: